Compare KIDS & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | VALN |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 536.9M |
| IPO Year | 2016 | 2021 |
| Metric | KIDS | VALN |
|---|---|---|
| Price | $18.64 | $5.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $24.67 | $15.50 |
| AVG Volume (30 Days) | ★ 101.7K | 28.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.42 | $5.06 |
| 52 Week High | $23.70 | $12.25 |
| Indicator | KIDS | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 39.49 |
| Support Level | $15.43 | $5.11 |
| Resistance Level | $18.94 | $6.69 |
| Average True Range (ATR) | 0.75 | 0.19 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 96.47 | 23.45 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.